Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | $510K | $8.01M | $194K | $688K | $1.20M | $659K | $0.00 | $0.00 | $0.00 |
| Revenue growth | — | — | 1471.5% | -97.6% | 255.5% | 74.1% | -45.0% | -100.0% | — | — |
| Gross profit | — | $51.0K | $833K | $12.1K | $159K | $260K | $141K | $0.00 | — | — |
| Gross margin | — | 10.0% | 10.4% | 6.3% | 23.2% | 21.7% | 21.3% | — | — | — |
| Operating income | $43.4K | -$2.25K | $516K | -$423K | -$130K | -$7.69M | -$15.9M | -$8.80M | -$38.0K | -$154K |
| Operating margin | — | -0.4% | 6.4% | -218.4% | -19.0% | -642.5% | -2410.0% | — | — | — |
| Net income | -$43.4K | -$2.25K | $420K | -$372K | -$117K | -$7.70M | -$15.9M | -$8.81M | -$42.3K | -$101K |
| Net margin | — | -0.4% | 5.2% | -192.0% | -17.1% | -642.8% | -2410.2% | — | — | — |
| EPS (diluted) | $0.00 | $0.00 | $0.01 | -$0.01 | $0.00 | — | -$0.26 | -$0.15 | $0.00 | $0.00 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$34.7K | -$463K | -$140K | -$59.7K | -$199K | $299K | -$147K | -$15.4K | -$36.7K | -$196K |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $2.53K | $36.8K | $1.15K | $1.47K | $18.1K | $95.2K | $5.85K | $376.00 | $476.00 | $4.10K |
| Total assets | $2.53K | $548K | $1.48M | $932K | $998K | $761K | $687K | $58.5K | $32.0K | $14.1K |
| Total liabilities | $17.3K | $37.0K | $241K | $134K | $312K | $117K | $201K | $315K | $327K | — |
| Shareholders' equity | -$14.8K | $511K | $1.24M | $798K | $686K | $644K | $486K | -$257K | -$295K | -$387K |
| Retained earnings | -$92.0K | -$94.2K | $325K | -$121K | -$239K | -$7.94M | -$23.8M | -$32.6M | -$32.7M | -$32.8M |
| Shares (wtd avg diluted) | 15.7M | 47.7M | 47.8M | 47.8M | 47.8M | 53.8M | 60.0M | 60.0M | 60.0M | 60.0M |
Every figure is extracted from ACRO BIOMEDICAL CO., LTD.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.